During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow -0.1% to 12824. S&P -0.17% to 1356. Nasdaq +0.02% to 2930.
Treasurys: 30-year -0.03%. 10-yr -0.26%. 5-yr -0.01%.
Commodities: Crude +0.04% to $81. Gold -0.03% to $1607.95.
Currencies: Euro +0.13% vs. dollar. Yen +0.77%. Pound +0.06%.
After Hours News:
Sonic (SONC): FQ3 EPS of $0.24 beats by $0.02. Revenue of $149M (-1.8% Y/Y) in-line. Shares +1.7% AH
Steelcase (SCS): Q1 EPS of $0.13 in-line. Revenue of $675M (+5.6% Y/Y) misses by $6M. Shares +0.5% AH.
Sun Healthcare (SUNH) resumes trading +35.2% AH after announcing it agreed to be acquired by Genesis HealthCare for $8.50/share.
FDA panel votes 11-0 in favor of the risk/benefit assessment for Onyx Pharmaceuticals' (ONXX) Kyprolis (carfilzomib) cancer drug for multiple myeloma. ONXX shares have been halted since ~12:30, but Ligand Pharma (LGND), which is due to receive milestone payments and royalties for the drug, rose 12.8% during regular trading and is +3.8% AH
Steelcase (SCS): Q1 EPS of $0.13 in-line. Revenue of $675M (+5.6% Y/Y) misses by $6M. Shares +0.5% AH.
Sun Healthcare (SUNH) resumes trading +35.2% AH after announcing it agreed to be acquired by Genesis HealthCare for $8.50/share.
FDA panel votes 11-0 in favor of the risk/benefit assessment for Onyx Pharmaceuticals' (ONXX) Kyprolis (carfilzomib) cancer drug for multiple myeloma. ONXX shares have been halted since ~12:30, but Ligand Pharma (LGND), which is due to receive milestone payments and royalties for the drug, rose 12.8% during regular trading and is +3.8% AH
Red Hat (RHT): FQ1 EPS of $0.30 beats by $0.03. Revenue of $314.7M (+19% Y/Y) beats by $3.9M. Deferred revenue totaled $913.3M at quarter's end, up 16% Y/Y but down 4% Q/Q. Shares -11.3% AH.
Bed Bath & Beyond (BBBY): Q1 EPS of $0.89 beats by $0.04. Revenue of $2.22B (+5% Y/Y) in-line. Shares -10.1% AH
Bed Bath & Beyond (BBBY): Q1 EPS of $0.89 beats by $0.04. Revenue of $2.22B (+5% Y/Y) in-line. Shares -10.1% AH
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
